Anemia in patients with midgut carcinoid, treated with alpha interferon: Effects by erythropoietin treatment on the perceived quality of life

European Journal of Cancer Care

Volumn 17, Issue 2, 2008, Pages 200-204

  Larsson, G ^a   Janson, E T ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Erythropoietin; Interferon; Midgut carcinoid; Quality of life

Indexed keywords

EID: 39749111215     PISSN: 09615423     EISSN: 13652354     Source Type: Journal    
DOI: 10.1111/j.1365-2354.2007.00844.x     Document Type: Article

References (26)

1. Aaronson N.K., Ahmedzai S., Bergman B., Bullinger M., Cull A., Duez N.J., Filiberti A., Flechtner H., Fleishman S.B., De Haes J.C., Kaasa S., Klee M., Osboa D., Razavi D., Rofe P.B., Schraub S., Sneeuw K., Sullivan M. & Takeda F. (1993) The European Organization for Research and Treatment of Cancer QLQ‐C30: a quality‐of‐life instrument for use in international clinical trials in oncology. Journal of National Cancer Institute 85, 365–376.
2. Afdhal N.H., Dieterich D.T., Pockros P.J., Schiff E.R., Shiffman M.L., Sulkowski M.S., Wright T., Younossi Z., Goon B.L., Tang K.L. & Bowers P.J. (2004) Epoetin alfa maintains ribavirin dose in HCV‐infected patients: a prospective, double‐blind, randomized controlled study. Gastroenterology 126, 1302–1311.
3. Aul C., Gattermann N., Germing U. & Heyll A. (1997) Adverse effects of interferon treatment. In: Interferons: Biological Activities and Clinical Efficacy (eds Aul C. & Schneider W.), pp. 250–266. Springer‐Verlag, New York, NY, USA.
4. Bokemeyer C., Aapro M.S., Courdi A., Foubert J., Link H., Osterborg A., Repetto L. & Soubeyran P. (2004) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. European Journal of Cancer 40, 2201–2216.
5. Cella D. (1997) The Functional Assessment of Cancer Therapy‐Anemia (FACT‐An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Seminars in Hematology 34, 13–19.
6. Demetri G.D. (2001) Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy. British Journal of Cancer 84 (Suppl. 1), 31–37.
7. Dieterich D.T., Wasserman R., Brau N., Hassanein T.I., Bini E.J., Bowers P.J. & Sulkowski M.S. (2003) Once‐weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus‐infected patients receiving ribavirin plus interferon alfa. American Journal of Gastroenterology 98, 2491–2499.
8. Fayers P.M. & Machin D. (2000) Quality of Life: Assessment, Analysis and Interpretation. John Wiley & Sons, Chichester, UK.
9. Glaspy J. & Cavill I. (1999) Role of iron in optimizing responses of anemic cancer patients to erythropoietin. Oncology (Huntingt) 13, 461–73 ;Discussion 477–8, 483–488.
10. Glaspy J., Bukowski R., Steinberg D., Taylor C., Tchekmedyian S. & Vadhan‐Raj S. (1997) Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. Journal of Clinical Oncology 15, 1218–1234.
11. Glimelius B., Linne T., Hoffman K., Larsson L., Svensson J.H., Nasman P., Svensson B. & Helmers C. (1998) Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer. Journal of Clinical Oncology 16, 434–440.
12. King M.T. (1996) The interpretation of scores from the EORTC quality of life questionnaire QLQ‐C30. Quality of Life Research 5, 555–567.
13. Kotasek D., Steger G., Faught W., Underhill C., Poulsen E., Colowick A.B., Rossi G. & Mackey J. (2003) Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double‐blind, placebo‐controlled, randomised study. European Journal of Cancer 39, 2026–2034.
14. Larsson G., Von Essen L. & Sjödén P.O. (1998) Quality of life in patients with endocrine tumors of the gastrointestinal tract: patient and staff perceptions. Cancer Nursing 21, 411–420.
15. Larsson G., Von Essen L. & Sjödén P.O. (1999) Health‐related quality of life in patients with endocrine tumours of the gastrointestinal tract. Acta Oncologica 38, 481–490.
16. Larsson G., Haglund K. & Von Essen L. (2003) Distress, quality of life and strategies to ‘keep a good mood’ in patients with carcinoid tumours: patient and staff perceptions. European Journal of Cancer Care (Engl) 12, 46–57.
17. Littlewood T.J., Bajetta E., Nortier J.W., Vercammen E. & Rapoport B. (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology 19, 2865–2874.
18. Öberg K. (1997) Interferon therapy of neuroendocrine tumors. In: Interferons: Biological Activities and Clinical Efficacy (eds Aul C. & Schneider W.), pp. 36–46. Springer‐Verlag, Berlin, German.
19. Osoba D., Rodrigues G., Myles J., Zee B. & Pater J. (1998) Interpreting the significance of changes in health‐related quality‐of‐ life scores. Journal of Clinical Oncology 16, 139–144.
20. Osterborg A. (1998) Recombinant human erythropoietin (rHuEPO) therapy in patients with cancer‐related anaemia: what have we learned? Medical Oncology 15 (Suppl. 1), S47–S49.
21. Pockros P.J., Shiffman M.L., Schiff E.R., Sulkowski M.S., Younossi Z., Dieterich D.T., Wright T.L., Mody S.H., Tang K.L., Goon B.L., Bowers P.J., Leitz G. & Afdhal N.H. (2004) Epoetin alfa improves quality of life in anemic HCV‐infected patients receiving combination therapy. Hepatology 40, 1450–1458.
22. Repetto L., Moeremans K. & Annemans L. (2006) European guidelines for the management of chemotherapy‐induced anaemia and health economic aspects of treatment. Cancer Treatment Review 32 (Suppl. 2), S5–S9.
23. Ringdal G.I. & Ringdal K. (1993) Testing the EORTC Quality of Life Questionnaire on Cancer Patients With Heterogeneous Diagnoses. Quality of Life Research 2, 129–140.
24. Rizzo J.D., Lichtin A.E., Woolf S.H., Seidenfeld J., Bennett C.L., Cella D., Djulbegovic B., Goode M.J., Jakubowski A.A., Lee S.J., Miller C.B., Rarick M.U., Regan D.H., Browman G.P. & Gordon M.S. (2002) Use of epoetin in patients with cancer: evidence‐based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Journal of Clinical Oncology 20, 4083–4107.
25. Wright M., Forton D., Main J., Goldin R., Torok E., Tedder R., Grant P., Thursz M., Naoumov N., Millson C., Mills P.R., Bassendine M. & Thomas H.C. (2005) Treatment of histologically mild hepatitis C virus infection with interferon and ribavirin: a multicentre randomized controlled trial. Journal of Viral Hepatitis 12, 58–66.
26. Yellen S.B., Cella D.F., Webster K., Blendowski C. & Kaplan E. (1997) Measuring fatigue and other anemia‐related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. Journal of Pain Symptom Management 13, 63–74.